Skip to main content
. 2022 Dec 29;64(2):100324. doi: 10.1016/j.jlr.2022.100324

Fig. 1.

Fig. 1

Liver FGFR4 KD improves liver steatosis. A: mRNA expression of Fgfr4 in liver and ileum biopsies. Data were normalized by the gene expression in the chow diet group. B: Immunoblotting of FGFR4 from liver biopsies from mice receiving either a saline solution or 3 mg/kg of siRNA targeting FGFR4 and its quantitative analysis. Measure of Fgfr1, 2, and 3 gene expressions from liver (C) and ileum (D) biopsies. Data were normalized by the gene expression in the chow diet group. Liver weight (E) and hepatic triglyceride (TG) content (F) after 12 weeks of diet. G: Liver steatosis score (0 = healthy, 1 = mild, 2 = moderate, and 3 = severe) calculated from hematoxylin and eosin (H&E)-stained liver (I). H: Serum levels of alanine transaminase (ALT). Data are expressed as mean ± SEM (n = 4–8, ns = non-significant, ∗ P < 0.05; ∗∗ P<0.01; ∗∗∗ P < 0.001; ∗∗∗∗P < 0.0001, two-way ANOVA followed by a Tukey’s multiple comparisons test). FGFR, fibroblast growth factor receptor; KD, knockdown.